# A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

> **NCT06624644** · PHASE2,PHASE3 · RECRUITING · sponsor: **Linnaeus Therapeutics, Inc.** · enrollment: 135 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)
- Melanoma Stage IIIB-IV
- Cutaneous Melanoma
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** LNS8801
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Chemotherapy (dacarbazine or temozolomide)
- **BIOLOGICAL:** Immunotherapy (Pembrolizumab)
- **BIOLOGICAL:** Immunotherapy (nivolumab and relatlimab)
- **BIOLOGICAL:** Immunotherapy (ipilimumab and nivolumab)

## Key facts

- **NCT ID:** NCT06624644
- **Lead sponsor:** Linnaeus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2029-02
- **Final completion:** 2031-02
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06624644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06624644, "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06624644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*